代謝型グルタミン酸受容体2治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0480
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Metabotropic Glutamate Receptor 2 – Pipeline Review, H2 2019
Summary

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Treatment Resistant Depression, Depression, Drug Addiction, Psychosis, Anxiety Disorders, Dementia, Dementia Associated With Alzheimer’s Disease, Epilepsy, Ischemia, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Post-Traumatic Stress Disorder (PTSD) and Stroke.

The latest report Metabotropic Glutamate Receptor 2 – Pipeline Review, H2 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
- The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Overview
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Johnson & Johnson
Mediti Pharma Inc
Merck & Co Inc
Taisho Pharmaceutical Holdings Co Ltd
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Drug Profiles
ADX-92639 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMT-133218 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-40411813 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5515 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-341495 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGS-0274 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-0069330 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGlu2 for Anxiety and Depression – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Dormant Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Discontinued Products
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) – Product Development Milestones
Featured News & Press Releases
Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy
Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD
Feb 27, 2017: Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms
Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms
Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia
Sep 02, 2010: Addex’s mGluR2 Shows Efficacy In Alzheimer’s Disease Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Addex Therapeutics Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Camino Pharma LLC, H2 2019
Pipeline by Denovo Biopharma LLC, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Mediti Pharma Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

【掲載企業】

Addex Therapeutics Ltd
Bristol-Myers Squibb Co
Camino Pharma LLC
Denovo Biopharma LLC
Eli Lilly and Co
Johnson & Johnson
Mediti Pharma Inc
Merck & Co Inc
Taisho Pharmaceutical Holdings Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[代謝型グルタミン酸受容体2治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆